Azenta Enters Definitive Agreement for the Sale of its B Medical Systems Business to THELEMA S.À R.L.
Rhea-AI Summary
Azenta (NASDAQ: AZTA) signed a binding agreement to sell its B Medical Systems business to THELEMA S.À R.L. for a purchase price of US$63 million. The sale is expected to close on or before March 31, 2026. Azenta described the divestiture as a step to simplify its portfolio and prioritize core capabilities, and said proceeds will be deployed to strengthen the company and support long-term value creation for shareholders. William Blair served as exclusive financial advisor and Taylor Wessing served as legal counsel.
Positive
- Sale price of US$63 million
- Transaction intended to simplify portfolio and prioritize core capabilities
- Proceeds to be deployed to strengthen the company and drive shareholder value
- Expected closing on or before March 31, 2026
Negative
- Divestiture transfers ownership of B Medical Systems refrigeration business
- Transaction remains subject to closing conditions through March 31, 2026
News Market Reaction – AZTA
On the day this news was published, AZTA declined 0.20%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Key peers in Medical Instruments & Supplies (e.g., BLFS, STAA, ATRC, NNNN, PLSE) all showed negative moves today, with price changes from -0.81% to -11.84%, contrasting with AZTA’s modest gain of 0.7% pre‑news.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 10 | Share repurchase plan | Positive | +2.5% | Board-approved <b>$250M</b> share buyback authorization through <b>Dec 31, 2028</b>. |
| Nov 21 | Earnings results | Positive | +16.3% | Q4 and FY2025 revenue growth with higher adjusted EBITDA margin and guidance. |
| Nov 12 | Earnings call notice | Neutral | -2.9% | Announcement of timing and access details for Q4 and FY2025 results call. |
| Nov 4 | Strategic partnership | Positive | +1.2% | Partnership with PRECEDE Foundation supporting early pancreatic cancer detection. |
| Oct 15 | Investor event | Neutral | +4.7% | Announcement of Investor Day at Indianapolis biorepository facility with webcast. |
AZTA has reacted positively to strategic and capital allocation updates, while more routine conference and event announcements have shown mixed and sometimes negative price reactions.
This announcement follows several shareholder-focused moves for Azenta. On Dec 10, 2025, the company authorized a $250M share repurchase program, which coincided with a 2.53% gain. Fourth quarter and full-year 2025 results released on Nov 21, 2025 showed revenue of $159M for Q4 and $594M for the year, with a 16.3% price reaction. Earlier, a partnership to support early detection of pancreatic cancer and investor-focused events such as an Investor Day and earnings call announcements also shaped investor perception. The current business divestiture continues that strategic portfolio evolution.
Market Pulse Summary
This announcement details Azenta’s agreement to sell its B Medical Systems business for US$63M, with closing targeted on or before March 31, 2026. It follows recent steps like a $250M buyback authorization and FY2025 results highlighting revenue growth and margin expansion. Together, these moves indicate ongoing portfolio and capital allocation activity. Investors may watch for updates on how sale proceeds are deployed and how remaining operations perform against prior growth and margin benchmarks.
AI-generated analysis. Not financial advice.
"The agreement to sell B Medical Systems marks a major step forward in simplifying the portfolio to prioritize our core capabilities with the highest strategic impact," said John Marotta, President and CEO. "The proceeds from this sale will be deployed to strengthen the company and drive long-term profitable value creation for our shareholders."
B Medical Systems is a global manufacturer and distributor of medical refrigeration devices based in Luxembourg.
William Blair served as exclusive financial advisor and Taylor Wessing served as legal counsel to Azenta for this transaction.
About Azenta Life Sciences
Azenta, Inc. (Nasdaq: AZTA) is a leading provider of life sciences solutions worldwide, enabling life science organizations around the world to bring impactful breakthroughs and therapies to market faster. Azenta provides a full suite of reliable cold-chain sample management solutions and multiomics services across areas such as drug development, clinical research and advanced cell therapies for the industry's top pharmaceutical, biotech, academic and healthcare institutions globally. Our global team delivers and supports these products and services through our industry-leading brands, including GENEWIZ, FluidX, Ziath, 4titude, Limfinity, Freezer Pro, and Barkey.
Azenta is headquartered in
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements, including the expected closing date for the transaction. Such statements involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Although the Company's forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by the Company. As a result, you are cautioned not to rely on these forward-looking statements. Any forward-looking statement made in this press release on Form 8-K speaks only as of the date on which it is made. Except as required by applicable law, the Company undertakes no obligation to publicly update or revise any forward-looking statement, whether because of new information, future developments or otherwise.
INVESTOR CONTACTS:
Yvonne Perron
Vice President, Financial Planning & Analysis, and Investor Relations
ir@azenta.com
Maria Isabel Cuartas
Manager, Investor Relations
ir@azenta.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/azenta-enters-definitive-agreement-for-the-sale-of-its-b-medical-systems-business-to-thelema-sa-rl-302649500.html
SOURCE Azenta
FAQ
What did Azenta (AZTA) announce on December 29, 2025 regarding B Medical Systems?
When is the Azenta (AZTA) sale of B Medical Systems expected to close?
How will Azenta (AZTA) use the proceeds from the B Medical Systems sale?
Who advised Azenta (AZTA) on the sale of B Medical Systems?
What business is being sold by Azenta (AZTA) in the transaction with THELEMA?
Does the Azenta (AZTA) sale of B Medical Systems change the company's strategic focus?
